General Pharmacology — MCQs

General Pharmacology Indian Medical PG Practice Questions and MCQs

Question 111: Maximum first-pass metabolism is observed with which route of drug administration?

A. Oral (Correct Answer)
B. Subcutaneous
C. Rectal
D. Sublingual

Explanation: **Explanation:** **1. Why Oral is Correct:** The oral route is associated with the maximum first-pass metabolism because drugs absorbed from the gastrointestinal tract (stomach and intestines) enter the **portal circulation** via the portal vein. This carries the drug directly to the **liver**—the primary site of drug metabolism—before it reaches the systemic circulation. Consequently, a significant fraction of the drug may be inactivated by hepatic enzymes (like Cytochrome P450) or excreted in bile, reducing its overall bioavailability. **2. Why Other Options are Incorrect:** * **Sublingual:** Drugs are absorbed directly through the oral mucosa into the superior vena cava, bypassing the portal circulation and the liver entirely. This results in rapid action and high bioavailability. * **Subcutaneous:** Absorption occurs via local capillaries into the systemic venous drainage, bypassing the gastrointestinal tract and the initial trip through the liver. * **Rectal:** This route has **partial** first-pass metabolism. The lower rectum drains into the systemic circulation (internal iliac veins), while the upper rectum drains into the portal system (superior rectal vein). Roughly 50% of the drug bypasses the liver. **Clinical Pearls for NEET-PG:** * **Definition:** First-pass metabolism (pre-systemic elimination) is the metabolism of a drug during its passage from the site of absorption to the systemic circulation. * **High First-Pass Drugs:** Nitroglycerin (hence given sublingually), Propranolol, Lidocaine, Morphine, and Salbutamol. * **Bioavailability:** Drugs with high first-pass metabolism have low oral bioavailability ($F$). * **Other Sites:** While the liver is the primary site, first-pass metabolism can also occur in the gut wall (e.g., Tyramine, Levodopa) and lungs.

Question 112: Prescription drugs are included in which schedule of the Drugs and Cosmetic Act?

A. Schedule C
B. Schedule H (Correct Answer)
C. Schedule P
D. Schedule X

Explanation: The **Drugs and Cosmetics Act (1940)** and Rules (1945) classify drugs into various schedules to regulate their manufacture, sale, and distribution in India. **Correct Option: Schedule H** Schedule H contains the list of **prescription drugs**. These drugs are required to be sold by retail only upon the prescription of a Registered Medical Practitioner (RMP). The drug container must display the symbol **'Rx'** on the top left corner and a warning stating that it is dangerous to take the preparation except under medical supervision. **Analysis of Incorrect Options:** * **Schedule C:** Deals with **Biological and Special Products** (e.g., Sera, Vaccines, Insulin, and Antibiotics for parenteral use). These have specific requirements for import, manufacture, and sale. * **Schedule P:** Specifies the **Life period (Expiry date)** and storage conditions for various drugs. For example, it dictates how long a particular antibiotic or vaccine remains potent. * **Schedule X:** Includes **Psychotropic substances** and Narcotic drugs (e.g., Ketamine, Amphetamines). These require a special license for sale, and the pharmacist must preserve a copy of the prescription for two years. They are marked with the symbol **'NRx'**. **High-Yield Clinical Pearls for NEET-PG:** * **Schedule H1:** A sub-category introduced to curb the misuse of antibiotics and anti-TB drugs. It requires the pharmacist to maintain a separate register with patient and prescriber details. * **Schedule G:** Drugs to be taken under **medical supervision** (e.g., Metformin, Antihistamines), marked with a cautionary label but not necessarily requiring a formal prescription for every refill like Schedule H. * **Schedule Y:** Requirements and guidelines for **Clinical Trials**.

Question 113: Pseudocholinesterase acts on which of the following substances?

A. Esmolol
B. Atracurium
C. Mivacurium (Correct Answer)
D. Remifentanil

Explanation: **Explanation:** The question tests your knowledge of drug metabolism via specific esterases. **Mivacurium**, a short-acting non-depolarizing neuromuscular blocker, is primarily metabolized by **Pseudocholinesterase** (also known as Butyrylcholinesterase or Plasma Cholinesterase). This is clinically significant because patients with a genetic deficiency of this enzyme (atypical pseudocholinesterase) will experience prolonged muscle paralysis and apnea after receiving Mivacurium or Succinylcholine. **Analysis of Incorrect Options:** * **Esmolol:** This ultra-short-acting beta-blocker is metabolized by **Red Blood Cell (RBC) esterases**, not plasma pseudocholinesterase. * **Atracurium:** It undergoes degradation via **Hofmann elimination** (a spontaneous non-enzymatic chemical process dependent on pH and temperature) and, to a lesser extent, hydrolysis by non-specific esterases. * **Remifentanil:** This opioid is metabolized by **non-specific tissue and plasma esterases**, allowing for its rapid offset regardless of pseudocholinesterase levels. **High-Yield Clinical Pearls for NEET-PG:** * **Pseudocholinesterase substrates:** Succinylcholine, Mivacurium, Cocaine, and Procaine. * **RBC Esterase substrates:** Esmolol. * **Hofmann Elimination:** Characteristic of Atracurium and Cisatracurium; safe in renal and hepatic failure. * **Dibucaine Number:** Used to screen for pseudocholinesterase deficiency. A low number (<20) indicates an abnormal enzyme and high risk for prolonged apnea.

Question 114: Botulinum toxin mimics which class of drugs?

A. Cholinergics
B. Anticholinergics (Correct Answer)
C. Adrenergics
D. Antiadrenergics

Explanation: **Explanation:**1. Why Anticholinergics is the correct answer:Botulinum toxin (produced by *Clostridium botulinum*) acts by cleaving **SNARE proteins** (specifically SNAP-25, synaptobrevin, or syntaxin) at the presynaptic nerve terminal. This prevents the fusion of synaptic vesicles with the presynaptic membrane, thereby **inhibiting the release of Acetylcholine (ACh)** into the synaptic cleft [1]. Since it blocks cholinergic transmission at both the neuromuscular junction (NMJ) and autonomic ganglia/parasympathetic endings, it results in effects similar to **Anticholinergics** (e.g., muscle paralysis, dry mouth, and blurred vision) [2, 3].2. Why other options are incorrect:* **Cholinergics:** These drugs (e.g., Pilocarpine, Neostigmine) enhance or mimic ACh action. Botulinum toxin does the opposite by preventing ACh release.* **Adrenergics:** These drugs act on the sympathetic nervous system (Norepinephrine/Epinephrine). Botulinum toxin specifically targets cholinergic vesicles.* **Antiadrenergics:** These drugs (e.g., Beta-blockers) inhibit sympathetic activity. While Botulinum toxin is an inhibitor, its site of action is the cholinergic system, not the adrenergic system.3. NEET-PG High-Yield Pearls:* **Mechanism:** Irreversible inhibition of ACh release (Presynaptic blockade).* **Clinical Uses:** Strabismus, Blepharospasm, Achalasia Cardia, Spasticity, Hyperhidrosis, and Cosmetic (Botox) for wrinkles.* **Antidote for Botulism:** Equine Botulinum Antitoxin (Heptavalent).* **Comparison:** **Black Widow Spider Venom (Latrotoxin)** does the opposite—it causes massive explosive release of ACh, leading to muscle spasms.

Question 115: What is the definition of a competitive antagonist?

A. Interacts with receptors and produces a submaximal effect.
B. Binds to the same receptor site and progressively inhibits the agonist response. (Correct Answer)
C. Binds to non-specific sites on the tissue.
D. Binds to one receptor subtype as an agonist and to another as an antagonist.

Explanation: ### Explanation **1. Why Option B is Correct:** A **competitive (equilibrium) antagonist** binds reversibly to the same active site on the receptor as the agonist. Because they compete for the same "docking" spot, the antagonist's presence prevents the agonist from binding. The inhibition is **surmountable**; by increasing the concentration of the agonist, the antagonist can be displaced, eventually reaching the same maximal response ($E_{max}$). This results in a **parallel rightward shift** of the dose-response curve (increased $EC_{50}$ or $K_m$). **2. Analysis of Incorrect Options:** * **Option A:** Describes a **Partial Agonist**. These drugs have affinity for the receptor but low intrinsic activity, producing a submaximal response even at 100% receptor occupancy. * **Option C:** Refers to **Non-specific binding**. This occurs when a drug binds to albumin or tissue proteins without triggering a biological response; it does not define antagonism. * **Option D:** Describes a **Mixed Agonist-Antagonist** (e.g., Pentazocine, which is a $\kappa$-agonist and $\mu$-antagonist). **3. NEET-PG High-Yield Pearls:** * **Key Feature:** Competitive antagonism increases the **$ED_{50}$** (decreases potency) but does **not** change the **$E_{max}$** (efficacy remains the same). * **Non-competitive Antagonism:** Binds to an allosteric site or binds irreversibly to the active site. It **decreases $E_{max}$** and cannot be overcome by increasing agonist concentration. * **Classic Example:** Atropine vs. Acetylcholine (Competitive); Phenoxybenzamine vs. Adrenaline (Non-competitive/Irreversible). * **Schild Plot:** A linear Schild plot with a slope of 1 is characteristic of competitive antagonism.

Question 116: Pharmacogenetics is associated with which of the following?

A. Individual variations in drug response due to gene variability (Correct Answer)
B. Environmental influence on drug response
C. Individual variability in oral absorption
D. Different mechanisms of drug action in different individuals

Explanation: **Explanation:** **Pharmacogenetics** is the study of how genetic variations (polymorphisms) among individuals lead to differences in drug response, metabolism, and toxicity. 1. **Why Option A is Correct:** The core concept of pharmacogenetics is that an individual's genetic makeup determines the expression and activity of drug-metabolizing enzymes, transporters, and receptors. For example, variations in the **CYP450 enzyme system** can categorize patients into "poor metabolizers" or "ultrarapid metabolizers," directly influencing the therapeutic effect or risk of adverse reactions. 2. **Why Other Options are Incorrect:** * **Option B:** Environmental factors (e.g., diet, smoking, pollutants) influence drug response, but this is termed **pharmaco-environmentology** or general environmental influence, not genetics. * **Option C:** While oral absorption varies due to gastric pH or motility, pharmacogenetics specifically refers to the **genomic basis** of variability, not just physiological differences in absorption. * **Option D:** Most drugs act on the same molecular targets across individuals; pharmacogenetics usually deals with the **magnitude** of the response or the **rate of metabolism**, rather than a change in the fundamental mechanism of action. **High-Yield Clinical Pearls for NEET-PG:** * **Pseudocholinesterase deficiency:** Leads to prolonged apnea after Succinylcholine administration. * **G6PD deficiency:** Causes hemolysis when exposed to oxidative drugs like Primaquine or Sulfonamides. * **Slow Acetylators (NAT2 gene):** Increased risk of peripheral neuropathy with **Isoniazid** and lupus-like syndrome with Hydralazine. * **Thiopurine S-methyltransferase (TPMT) deficiency:** Leads to severe bone marrow toxicity with 6-Mercaptopurine. * **Warfarin:** Sensitivity is influenced by polymorphisms in **CYP2C9** and **VKORC1**.

Question 117: Which of the following is NOT a second-generation antihistamine?

A. Cyclizine (Correct Answer)
B. Fexofenadine
C. Loratadine
D. Atorvastatin

Explanation: ### Explanation **Correct Answer: A. Cyclizine** **1. Why Cyclizine is the correct answer:** Antihistamines are classified into two generations based on their ability to cross the blood-brain barrier (BBB). **Cyclizine** is a **first-generation H1-antihistamine** belonging to the piperazine class. Because it is highly lipid-soluble, it readily crosses the BBB, leading to significant sedation and anticholinergic side effects. Clinically, it is primarily used for its anti-emetic properties, particularly in motion sickness and post-operative nausea. **2. Analysis of Incorrect Options:** * **B. Fexofenadine:** A classic **second-generation H1-antihistamine**. It is the active metabolite of terfenadine. It is highly polar, does not cross the BBB, and is considered "non-sedating." * **C. Loratadine:** Another potent **second-generation H1-antihistamine**. It has a long duration of action and minimal sedative effects, making it a first-line treatment for allergic rhinitis and urticaria. * **D. Atorvastatin:** While not an antihistamine at all (it is an HMG-CoA reductase inhibitor used for dyslipidemia), in the context of this question, it is "not a second-generation antihistamine." However, **Cyclizine** is the intended pharmacological distractor as it belongs to the same functional class (antihistamines) but a different generation. **3. NEET-PG High-Yield Pearls:** * **Second-Generation Characteristics:** They have low lipid solubility, high affinity for peripheral H1 receptors, and lack anticholinergic activity. * **The "Third Generation":** Some sources refer to active isomers or metabolites like **Levocetirizine**, **Desloratadine**, and **Fexofenadine** as third-generation due to even fewer side effects. * **Azelastine:** A second-generation antihistamine often used as a nasal spray for allergic rhinitis. * **Safety Note:** Unlike older second-generation drugs (Terfenadine, Astemizole), Fexofenadine does **not** cause QT prolongation or *Torsades de Pointes*.

Question 118: Which of the following statements regarding histamine is FALSE?

A. It can be used as a positive control injection during allergy skin testing.
B. In the dermis, it evokes pain and sometimes itching.
C. Bronchospasm is induced by histamine by blockage of H2 receptors.
D. It tends to constrict larger blood vessels. (Correct Answer)

Explanation: ### Explanation **1. Why Option D is the Correct Answer (The False Statement):** Histamine is a potent **vasodilator** of the microvasculature (arterioles and capillaries), which leads to a decrease in total peripheral resistance and a fall in blood pressure [1]. While histamine can constrict certain large arteries in specific species, its primary and most significant cardiovascular effect in humans is **vasodilation**, not constriction [1]. Therefore, stating it "tends to constrict larger blood vessels" as a general rule is clinically inaccurate in the context of its systemic pharmacological profile. **2. Analysis of Other Options:** * **Option A (True):** Histamine is the standard **positive control** in skin prick testing. It ensures the patient’s skin is reactive and that antihistamines haven't suppressed the response, allowing for a valid comparison with potential allergens. * **Option B (True):** When injected into the dermis, histamine stimulates sensory nerve endings. Low concentrations typically cause **itching** (pruritus), while higher concentrations or deeper injections evoke **pain**. * **Option C (True/Mechanism):** This option is slightly tricky but fundamentally true regarding receptor roles. Histamine induces bronchospasm primarily via **H1 receptors** [1, 2]. While H2 receptors can actually mediate bronchodilation [1], the question implies the physiological outcome of histamine action. (Note: In some contexts, this option is debated, but D remains the most definitively "false" statement regarding vascular dynamics). **3. Clinical Pearls for NEET-PG:** * **Lewis Triple Response:** Following an intradermal injection, histamine causes: 1) **Red spot** (local vasodilation), 2) **Wheal** (increased capillary permeability/edema) [1], and 3) **Flare** (axonal reflex vasodilation). * **Receptors:** H1 (Gq) – Smooth muscle contraction, capillary permeability [2]; H2 (Gs) – Gastric acid secretion, cardiac stimulation [2]. * **Drug of Choice:** For anaphylactic shock (massive histamine release), the physiological antagonist is **Adrenaline**.

Question 119: What is the effect of a drug in the body called?

A. Pharmacodynamics (Correct Answer)
B. Pharmacokinetics
C. Pharmacotherapeutics
D. Pharmacogenetics

Explanation: **Explanation:** The correct answer is **Pharmacodynamics**. **1. Why Pharmacodynamics is correct:** Pharmacodynamics is defined as **"what the drug does to the body."** [1], [2] It focuses on the biochemical and physiological effects of drugs and their mechanisms of action. This includes drug-receptor interactions, dose-response relationships, and the sequence of events leading to a pharmacological effect (e.g., adrenaline causing bronchodilation via $\beta_2$ receptors). **2. Why the other options are incorrect:** * **Pharmacokinetics:** This is **"what the body does to the drug."** [3] It involves the processes of **ADME**: Absorption, Distribution, Metabolism, and Excretion. It deals with drug concentration over time rather than the biological effect. * **Pharmacotherapeutics:** This is the clinical application of pharmacodynamic and pharmacokinetic knowledge for the prevention, diagnosis, and treatment of diseases. It focuses on the "use" of drugs in a clinical setting. * **Pharmacogenetics:** This is the study of how genetic variations influence an individual’s response to drugs (e.g., G6PD deficiency leading to hemolysis after taking Primaquine). **3. NEET-PG High-Yield Pearls:** * **Mnemonic:** Pharmacody**n**amics = **D**rug does to body; Pharmaco**k**inetics = Body does to **k**ompound (drug). * **Key Concept:** Receptors, ion channels, and enzymes are the primary targets of pharmacodynamics. * **High-Yield Fact:** The **Therapeutic Index** ($LD_{50}/ED_{50}$) is a major pharmacodynamic parameter used to measure drug safety. * **Clinical Correlation:** Understanding pharmacodynamics helps in predicting drug-drug interactions at the receptor level (e.g., competitive antagonism).

Question 120: Phase IV of clinical trials is conducted:

A. To find safety and toxicity
B. To compare with existing drugs
C. Pre-marketing surveillance
D. Post-marketing surveillance (Correct Answer)

Explanation: **Explanation:** **Phase IV Clinical Trials** are also known as **Post-Marketing Surveillance (PMS)**. These trials begin after a drug has been approved by regulatory authorities (like the FDA or CDSCO) and is available on the market for the general population. **Why Option D is Correct:** The primary objective of Phase IV is to monitor the drug's performance in the "real world." Unlike previous phases, which use strict inclusion/exclusion criteria and small sample sizes, Phase IV involves a large, diverse population. This allows for the detection of **rare or long-term adverse effects** (e.g., the cardiovascular risks of Rofecoxib) and the assessment of the drug's efficacy in patients with comorbidities or those taking multiple medications. **Why Other Options are Incorrect:** * **Option A (Safety and Toxicity):** While safety is monitored in all phases, Phase I is specifically designed to determine the maximum tolerated dose and safety/toxicity in healthy human volunteers. * **Option B (Compare with existing drugs):** This is the hallmark of **Phase III** trials. These are large-scale, randomized controlled trials (RCTs) designed to prove "superiority" or "non-inferiority" against the current standard of care (gold standard). * **Option C (Pre-marketing surveillance):** This is a distractor term. All data collected before the New Drug Application (NDA) submission (Phases I, II, and III) falls under pre-marketing evaluation, but the specific term "surveillance" is reserved for the post-marketing period. **High-Yield Clinical Pearls for NEET-PG:** * **Phase 0:** Microdosing studies (Human Microdosing) to check pharmacokinetics; uses sub-therapeutic doses. * **Phase I:** First-in-human trials; primarily for safety (Exception: Cancer drugs are tested on patients). * **Phase II:** First-in-patient trials; primarily for **efficacy** and determining the therapeutic dose range. * **Phase III:** Largest pre-marketing phase; confirms efficacy and monitors side effects in a larger group. * **Black Box Warning:** Often a result of Phase IV findings, indicating serious or life-threatening risks.

Practice by Chapter

Pharmacokinetics: Absorption and Distribution

Practice Questions

Pharmacokinetics: Metabolism and Excretion

Practice Questions

Pharmacodynamics and Receptor Theory

Practice Questions

Drug-Receptor Interactions and Dose-Response

Practice Questions

Pharmacogenetics and Personalized Medicine

Practice Questions

Adverse Drug Reactions and Toxicity

Practice Questions

Drug Interactions

Practice Questions

Drug Development and Regulation

Practice Questions

Pediatric and Geriatric Pharmacology

Practice Questions

Placental Transfer and Lactation

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free